Compare Novo Nordisk A/S (NVO) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Rush Street Interactive Inc — how do they compare? Novo Nordisk A/S trades at $38.62 (market cap $165.31B), while Rush Street Interactive Inc trades at $18.9 (market cap $2.35B). The key difference: Novo Nordisk A/S is far larger — about 70.3× Rush Street Interactive Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Rush Street Interactive Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Rush Street Interactive Inc for 13 Days on average.
| NVO | RSI | |
|---|---|---|
Market Cap | $165.31B | $2.35B |
Volume | 11,432,838 | 2,219,374 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $34.52 |
52-Week Low | $35.29 | $15.89 |
Typical Hold Time | 116 Days | 13 Days |
Enterprise Value | $179.56B | $2.01B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
RSI (Rush Street Interactive) trades at $18.90, down 6.62% recently, with a bearish technical signal from moving averages. The company shows strong revenue growth from $1.13B in 2025 to $1.4B in 2026, though net income margin compressed to 2.33%. Recent Q2 2026 earnings beat expectations with EPS of $0.15 versus $0.1499 expected. Analyst consensus remains strongly bullish with 10 buy ratings and a $34.88 price target, representing 85% upside potential from current levels.
The stock presents significant upside based on analyst targets but faces execution risks amid competitive online gaming markets. High P/E ratio of 65.55 suggests premium valuation requiring sustained growth. Institutional interest remains strong with BlackRock's $448M investment in Q2 2026. Near-term performance hinges on Q3 earnings delivery and sports betting market expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
